Press Releases
2026 – Press Releases
Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models
September 10, 2026 | NetraMark Holdings
NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
August 27, 2026 | NetraMark Holdings
NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High
August 20, 2026 | NetraMark Holdings
NetraMark Reports Its Annual General And Special Meeting Results
July 14, 2026 | NetraMark Holdings
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
July 13, 2026 | NetraMark Holdings
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
July 9, 2026 | NetraMark Holdings
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
June 29, 2026 | NetraMark Holdings
NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
June 9, 2026 | NetraMark Holdings
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
May 20, 2026 | NetraMark Holdings
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
May 14, 2026 | NetraMark Holdings
NetraMark Announces Change To Board Of Directors
May 7, 2026 | NetraMark Holdings
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
May 4, 2026 | NetraMark Holdings
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
April 30, 2026 | NetraMark Holdings
NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
April 22, 2026 | NetraMark Holdings
NetraMark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
April 20, 2026 | NetraMark Holdings
NetraMark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
April 9, 2026 | NetraMark Holdings
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
March 25, 2026 | NetraMark Holdings
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
March 19, 2026 | NetraMark Holdings
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
March 11, 2026 | NetraMark Holdings
NetraMark Closes Final Tranche of $3.5 Million Private Placement
February 19, 2026 | NetraMark Holdings
Netramark Announces Uplisting to Toronto Stock Exchange
February 13, 2026 | NetraMark Holdings
NetraMark Strengthens Board Of Directors
January 29, 2026 | NetraMark Holdings
NetraMark Closes First Tranche of Private Placement
January 28, 2026 | NetraMark Holdings
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
January 22, 2026 | NetraMark Holdings
NetraMark Announces Private Placement Financing
January 13, 2026 | NetraMark Holdings
2025 – Press Releases
NetraMark Delivers Transformational Quarter Of Execution
December 18, 2025 | NetraMark Holdings
NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
December 16, 2025 | NetraMark Holdings
NetraMark Achieves Major FDA Milestone
December 15, 2025 | NetraMark Holdings
NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
December 11, 2025 | NetraMark Holdings
NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
December 8, 2025 | NetraMark Holdings
NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
November 18, 2025 | NetraMark Holdings
Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
November 3, 2025 | NetraMark Holdings
NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
October 29, 2025 | NetraMark Holdings
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
September 22, 2025 | NetraMark Holdings
NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
August 12, 2025 | NetraMark Holdings
Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
August 5, 2025 | NetraMark Holdings
NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
July 31, 2025 | NetraMark Holdings
NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
July 30, 2025 | NetraMark Holdings
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
July 28, 2025 | NetraMark Holdings
NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
June 23, 2025 | NetraMark Holdings
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
June 12, 2025 | NetraMark Holdings
NetraMark Completes 2025 Annual General Meeting
June 10, 2025 | NetraMark Holdings
NetraMark to Host Shareholder Conference Call to Discuss Business Momentum
April 10, 2025 | NetraMark Holdings | Join Call on Tuesday, April 15 at 4:00 – 4:30pm EST
NetraMark and Worldwide Clinical Trials Announce Agreement to Transform Clinical Trial Design with AI-Powered Insights
April 3, 2025 | NetraMark Holdings
NetraMark Strengthens Financial Position with $1,853,054 Raised from Warrant Exercise
March 10, 2025 | NetraMark Holdings
NetraMark Unveils AI Driven Insights for Major Depressive Disorder and Schizophrenia at ISCTM Conference
March 5, 2025 | NetraMark Holdings
NetraMark and the Ontario Brain Institute Partner to Advance AI-Powered Neuroanalytics for Major Depression Research
Feb 25, 2025 | NetraMark Holdings
NetraMark to Present Novel AI-Based Clinical Trial Treatment Separation Tools at ISCTM Annual Meeting
Feb 18, 2025 | NetraMark Holdings
NetraMark launches NetraAi 2.0: advancing clinical trial analysis with ai-powered insights
Feb 12, 2025 | NetraMark Holdings
NetraMark provides business update
Feb 4, 2025 | NetraMark Holdings
2024 – Press Releases
NetraMark strengthens financial position with $1,161,000 raised from warrant and stock option exercise
Dec 12, 2024 | NetraMark Holdings
Oncology commercialization leader P.J. Haley to join NetraMark board of directors
Oct 09, 2024 | NetraMark Holdings
NetraMark provides q3 business update and highlights progress
Aug 20, 2024 | NetraMark Holdings
NetraMark's ai-based clinical solution identifies novel lung and colon cancer biomarkers and patient subpopulations
April 10, 2024 | NetraMark Holdings
NetraMark provides business update and highlights progress
April 02, 2024 | NetraMark Holdings
NetraMark To Present New Data Highlighting The Utility Of Its AI Based Clinical Solution In Identifying Parkinson's Disease Associated Biomarkers At AD/PD™ 2024
February 29, 2024 | NetraMark Holdings
NetraMark To Present New Data Demonstrating The Power Of Its AI Based Technology To De-Risk Neurology Clinical Trials At ISCTM Annual Meeting
February 15, 2024 | NetraMark Holdings
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates
January 16, 2024 | NetraMark Holdings
NetraMark expands team with the addition of industry veteran
Dec 11, 2024 | NetraMark Holdings
NetraMark to present at the 2024 cantech letter conference in toronto, on
Oct 02, 2024 | NetraMark Holdings
NetraMark announces collaboration agreement with nimh to analyze clinical trial data on the use of ketamine in psychiatric disorders
June 10, 2024 | NetraMark Holdings
NetraMark announces shareholder meeting results
April 05, 2024 | NetraMark Holdings
NetraMark signs contract with pharmaceutical company to deliver clinical trial insights regarding efficacy and placebo response
March 12, 2024 | NetraMark Holdings
NetraMark Signs Fourth Contract With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
February 27, 2024 | NetraMark Holdings
NetraMark Announces Launch Of The Netra AI Lab
February 12, 2024 | NetraMark Holdings
NetraMark signs a pilot collaboration agreement with a top 5 pharmaceutical company
Dec 09, 2024 | NetraMark Holdings
NetraMark expands product offerings to address core clinical trial challenges and improve market access success
Sept 11, 2024 | NetraMark Holdings
NetraMark to introduce the treatment attitude profile (tap™) scale for placebo response persona discovery using its netra ai technology at the 2024 ascp annual meeting
May 28, 2024 | NetraMark Holdings
Pharmaceutical industry veteran joins NetraMark advisory board
April 04, 2024 | NetraMark Holdings
NetraMark's Ai-based clinical solution identifies parkinson's disease subtypes linked by mitochondrial, microbiome and immune signaling
March 11, 2024 | NetraMark Holdings
NetraMark's AI Based Technology Identifies Significant Drivers Of Efficacy And Placebo Responses And Has Potential To Improve Success Rates For Clinical Trials Of Psychiatric Medications
February 26, 2024 | NetraMark Holdings
NetraMark Signs Third Contract With Large Biopharmaceutical Company to Enhance Clinical Trial Insights
January 30, 2024 | NetraMark Holdings
2023 – Press Releases
NetraMark Signs Two Contracts With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
December 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Private Placement – Press Release Clarification
September 15, 2023 | NetraMark Holdings
NetraMark Announces Shares for Debt Settlement
July 5, 2023 | NetraMark Holdings
NetraMark Closes Second and Final Tranche of Private Placement
June 14, 2023 | NetraMark Holdings
NetraMark Announces Increase to Private Placement Financing
June 6, 2023 | NetraMark Holdings
NetraMark Selects Finn Partners As Its Public Relations Agency Of Record
November 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
September 11, 2023 | NetraMark Holdings
NetraMark Enters into Advisor Agreement
June 22, 2023 | NetraMark Holdings
NetraMark Closes First Tranche of Private Placement
June 9, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
June 1, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark as Chief Medical Officer Joins
November 7, 2023 | NetraMark Holdings
NetraMark Closes Private Placement Financing
September 19, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark Advisory Board
July 19, 2023 | NetraMark Holdings
NetraMark Announces Engagement of ARU Global Inc.
June 21, 2023 | NetraMark Holdings
NetraMark Announces Uplist to the OTCQB Market
June 7, 2023 | NetraMark Holdings
NetraMark to Attend American Society of Clinical Oncology Conference in Chicago
June 1, 2023 | NetraMark Holdings